We’re excited to share a vital Nemaline Myopathy research update from the front lines! Dr. Vandana Gupta‘s lab is making significant strides in two crucial areas of Nemaline Myopathy (NM) research: gene therapy for KLHL40-related NM and small molecule drug screening for KLHL41-related NM. These efforts are bringing us closer to understanding and treating this complex rare disease.
Breakthroughs in Gene Therapy for KLHL40-related NM
Dr. Gupta’s team has been diligently working with a mouse model of KLHL40-related NM to test different doses of a KLHL40-AAV (adeno-associated virus) gene replacement therapy. Their primary goal: to see if this gene therapy could improve survival and muscle function in affected mice.
Initial tests showed that low doses of the treatment didn’t yield significant improvements in survival or motor performance. However, a mid-range dose offered modest benefits, extending survival by a few days. The real breakthrough came with a higher dose, which led to remarkable results: treated mouse pups showed improved survival, gained more weight, and demonstrated better motor function. Crucially, these mice are now over 90 days old— an important milestone, given that untreated mice typically lose mobility by days 5-6 and don’t survive beyond days 10-11.
The team is continuing to evaluate the long-term effects of this promising treatment, including ongoing survival, motor skill assessment, and detailed analysis of muscle tissue after death to understand the therapy’s cellular impact. This part of the Nemaline Myopathy research update is particularly encouraging.
Promising Developments in Drug Screening for KLHL41-related NM
In parallel, Dr. Gupta’s lab is actively screening small molecule drugs for KLHL41-related NM using a zebrafish model. They’ve already screened approximately 1,400 FDA-approved drugs to identify potential candidates that could improve muscle function.
From this initial screening, 56 drugs showed early signs of improving motor function in the first round of testing. These promising compounds are now undergoing secondary screening to confirm their effectiveness, test various doses, and filter out any false positives.
The next critical phase involves expanding this work. The most promising drugs will be tested in other NM models, including those for KLHL40, NEB, and ACTA1-related NM. The ultimate goal is to identify treatments that can improve both motor function and survival across multiple NM genetic subtypes. This ongoing drug screening is a key part of our Nemaline Myopathy research.
Overcoming Challenges and Looking Ahead
While no major issues were reported, early delays occurred due to the time required to expand the mouse colony and reach sufficient survival levels to evaluate treatment effects. Now, with longer-living treated mice, the lab is well-positioned to conduct deeper analyses.
Next steps for Dr. Gupta’s lab include:
- Continuing long-term evaluation of gene therapy effects in KLHL40 mice.
- Completing the full drug library screen (approximately 1,500 compounds).
- Testing the most promising drugs across multiple NM genetic models.
Why This Research Matters
These ongoing efforts in Dr. Gupta’s lab represent a significant Nemaline Myopathy research update, bringing hope to the entire community. By pursuing both cutting-edge gene therapy and the repurposing of existing drugs, Dr. Gupta’s team is dedicated to finding near-term and long-term treatment options for different NM subtypes. This offers a clearer pathway toward improving the quality of life and extending survival for individuals living with Nemaline Myopathy.
Help Us Continue to Make Breakthroughs Like These
Donate to AFBS: Your monetary gift will support critical research and provide vital resources for NM families.
Stay Connected: Sign up for our email list to receive the latest updates from AFBS and learn more about NM research. Are you an individual or a caregiver of an individual affected by NM? Fill out the AFBS Contact Survey so we can connect you with valuable resources, support, and opportunities to get involved with upcoming research studies!